Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
32.74
+0.10 (0.31%)
At close: Oct 8, 2025, 4:00 PM EDT
32.51
-0.23 (-0.70%)
After-hours: Oct 8, 2025, 6:52 PM EDT
Genmab Revenue
Genmab had revenue of $925.00M in the quarter ending June 30, 2025, with 18.74% growth. This brings the company's revenue in the last twelve months to $3.65B, up 32.97% year-over-year. In the year 2024, Genmab had annual revenue of $2.99B with 22.32% growth.
Revenue (ttm)
$3.65B
Revenue Growth
+32.97%
P/S Ratio
5.51
Revenue / Employee
$1,359,762
Employees
2,682
Market Cap
20.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.99B | 545.24M | 22.32% |
| Dec 31, 2023 | 2.44B | 358.99M | 17.23% |
| Dec 31, 2022 | 2.08B | 796.62M | 61.88% |
| Dec 31, 2021 | 1.29B | -374.23M | -22.52% |
| Dec 31, 2020 | 1.66B | 855.79M | 106.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
GMAB News
- 7 days ago - MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS - Business Wire
- 9 days ago - Genmab A/S (GMAB) M&A Call Transcript - Seeking Alpha
- 9 days ago - Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough - Benzinga
- 9 days ago - This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired. - Barrons
- 9 days ago - Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline - Invezz
- 9 days ago - Genmab to buy Dutch cancer drugmaker Merus for $8 billion - Reuters
- 9 days ago - Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - Business Wire
- 13 days ago - Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewsWire